[
  {
    "ts": "2026-01-23T06:30:00+00:00",
    "headline": "AbbVie Dodged a Patent Disaster, and Shares Gained 460%. Merck and Bristol Myers Are Next.",
    "summary": "AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers Squibb face similar patent cliffs.",
    "url": "https://www.barrons.com/articles/abbvie-dodged-a-patent-disaster-and-shares-gained-460-merck-and-bristol-myers-are-next-5968f3cd?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "ff057859-25cc-38ab-bf6d-78ba37dc9314",
      "content": {
        "id": "ff057859-25cc-38ab-bf6d-78ba37dc9314",
        "contentType": "STORY",
        "title": "AbbVie Dodged a Patent Disaster, and Shares Gained 460%. Merck and Bristol Myers Are Next.",
        "description": "",
        "summary": "AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers Squibb face similar patent cliffs.",
        "pubDate": "2026-01-23T06:30:00Z",
        "displayTime": "2026-01-23T06:30:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ff057859-25cc-38ab-bf6d-78ba37dc9314/abbvie-dodged-a-patent.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/90655360b7a4e125d540f8474523bc7f",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6BytADf.wdgQOFbGSuj0IA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/90655360b7a4e125d540f8474523bc7f.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aiR.2Irm6EXEA73p_uJuJQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/90655360b7a4e125d540f8474523bc7f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/abbvie-dodged-a-patent-disaster-and-shares-gained-460-merck-and-bristol-myers-are-next-5968f3cd?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-23T12:40:09+00:00",
    "headline": "Wall Street Has a Positive Opinion on Guardant Health (GH)",
    "summary": "​Guardant Health, Inc. (NASDAQ:GH) is one of the Best Russell 2000 Stocks to Buy Right Now. Wall Street has a positive opinion on Guardant Health, Inc. (NASDAQ:GH). Recently, on January 19, Guardant Health, Inc. (NASDAQ:GH) announced a multi-year partnership with Merck. The collaboration aims to support Merck’s oncology drug development and sales efforts through Guardant’s […]",
    "url": "https://finance.yahoo.com/news/wall-street-positive-opinion-guardant-124009109.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "93db8972-0e11-3910-a754-c6358096588a",
      "content": {
        "id": "93db8972-0e11-3910-a754-c6358096588a",
        "contentType": "STORY",
        "title": "Wall Street Has a Positive Opinion on Guardant Health (GH)",
        "description": "",
        "summary": "​Guardant Health, Inc. (NASDAQ:GH) is one of the Best Russell 2000 Stocks to Buy Right Now. Wall Street has a positive opinion on Guardant Health, Inc. (NASDAQ:GH). Recently, on January 19, Guardant Health, Inc. (NASDAQ:GH) announced a multi-year partnership with Merck. The collaboration aims to support Merck’s oncology drug development and sales efforts through Guardant’s […]",
        "pubDate": "2026-01-23T12:40:09Z",
        "displayTime": "2026-01-23T12:40:09Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/2a5225bbb1b6e607d0c46f4a4303fa02",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/97SaQhw9hgkkWBIiCsYPuA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/2a5225bbb1b6e607d0c46f4a4303fa02.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xU42mv4mpu6vnF0yEXHXww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/2a5225bbb1b6e607d0c46f4a4303fa02.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/wall-street-positive-opinion-guardant-124009109.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/wall-street-positive-opinion-guardant-124009109.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GH"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-23T13:36:00+00:00",
    "headline": "Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q4 Earnings",
    "summary": "LLY's oncology drugs, led by Verzenio and new launches, are set to support upcoming Q4 results as investor focus broadens beyond GLP-1s.",
    "url": "https://finance.yahoo.com/news/heres-eli-lillys-oncology-drugs-133600753.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "a902c7fb-d30a-336e-bdf1-87eb5d237bda",
      "content": {
        "id": "a902c7fb-d30a-336e-bdf1-87eb5d237bda",
        "contentType": "STORY",
        "title": "Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q4 Earnings",
        "description": "",
        "summary": "LLY's oncology drugs, led by Verzenio and new launches, are set to support upcoming Q4 results as investor focus broadens beyond GLP-1s.",
        "pubDate": "2026-01-23T13:36:00Z",
        "displayTime": "2026-01-23T13:36:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/3c8c5ffebabb5a0d6f7bffb8eb41c523",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Zg3ykhh14An2bfVuUvzbag--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3c8c5ffebabb5a0d6f7bffb8eb41c523.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8KeSNQWO2yQtdmAEk3F_Nw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3c8c5ffebabb5a0d6f7bffb8eb41c523.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/heres-eli-lillys-oncology-drugs-133600753.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-eli-lillys-oncology-drugs-133600753.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-23T17:14:21+00:00",
    "headline": "Why Analysts See Merck (MRK) Differently After The Latest Price Target Reset",
    "summary": "The latest update to the Merck stock story centers on a revised price target, reflecting how analysts are reassessing the company based on the most recent information available. This shift in expectations highlights how fresh data and evolving views on the business can influence what some see as a reasonable price level for the shares. Stay tuned to see how you can keep on top of these price target changes and the broader narrative around Merck going forward. Analyst Price Targets don't...",
    "url": "https://finance.yahoo.com/news/why-analysts-see-merck-mrk-171421974.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "f1c07346-a8e6-3b3d-8335-446dc14f57e6",
      "content": {
        "id": "f1c07346-a8e6-3b3d-8335-446dc14f57e6",
        "contentType": "STORY",
        "title": "Why Analysts See Merck (MRK) Differently After The Latest Price Target Reset",
        "description": "",
        "summary": "The latest update to the Merck stock story centers on a revised price target, reflecting how analysts are reassessing the company based on the most recent information available. This shift in expectations highlights how fresh data and evolving views on the business can influence what some see as a reasonable price level for the shares. Stay tuned to see how you can keep on top of these price target changes and the broader narrative around Merck going forward. Analyst Price Targets don't...",
        "pubDate": "2026-01-23T17:14:21Z",
        "displayTime": "2026-01-23T17:14:21Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kA84g.s9IO2ClCgTX6BCgg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DmY770n7xz5DXLM6ZHLmxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-analysts-see-merck-mrk-171421974.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-analysts-see-merck-mrk-171421974.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-23T18:05:00+00:00",
    "headline": "Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?",
    "summary": "Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.",
    "url": "https://www.fool.com/investing/2026/01/23/forget-eli-lilly-buy-these-unstoppable-stock/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "d36fc022-2457-3be0-9329-dd797eed60e8",
      "content": {
        "id": "d36fc022-2457-3be0-9329-dd797eed60e8",
        "contentType": "STORY",
        "title": "Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?",
        "description": "",
        "summary": "Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.",
        "pubDate": "2026-01-23T18:05:00Z",
        "displayTime": "2026-01-23T18:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/e6e25b0076ab1d65c4645d933a1ffa84",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "A hand drawing a scale showing price vs. value.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oH1vMW9a8lQPyVxDdje.yQ--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/e6e25b0076ab1d65c4645d933a1ffa84.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pM7HlYM_F0inHleq4d2DMA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/e6e25b0076ab1d65c4645d933a1ffa84.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/23/forget-eli-lilly-buy-these-unstoppable-stock/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/forget-eli-lilly-buy-unstoppable-180500495.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-23T17:50:00+00:00",
    "headline": "2 Soaring Stocks to Hold for the Next 20 Years",
    "summary": "They can power outstanding returns while providing stability to a well-diversified portfolio.",
    "url": "https://www.fool.com/investing/2026/01/23/2-soaring-stocks-to-hold-for-the-next-20-years/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "16c3dd5c-537d-3e82-9313-0c5e28acb981",
      "content": {
        "id": "16c3dd5c-537d-3e82-9313-0c5e28acb981",
        "contentType": "STORY",
        "title": "2 Soaring Stocks to Hold for the Next 20 Years",
        "description": "",
        "summary": "They can power outstanding returns while providing stability to a well-diversified portfolio.",
        "pubDate": "2026-01-23T17:50:00Z",
        "displayTime": "2026-01-23T17:50:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/7f536a3b92ad43276cf4de8f63d88e8e",
          "originalWidth": 1400,
          "originalHeight": 738,
          "caption": "A doctor and patient talking.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XdMrvDolQXX5Un7OemPHuw--~B/aD03Mzg7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/7f536a3b92ad43276cf4de8f63d88e8e.cf.webp",
              "width": 1400,
              "height": 738,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Ajuy3XhYzBIBeeX.CWkrcw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/7f536a3b92ad43276cf4de8f63d88e8e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/23/2-soaring-stocks-to-hold-for-the-next-20-years/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-soaring-stocks-hold-next-175000118.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-23T23:01:46+00:00",
    "headline": "Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month",
    "summary": "Today, Jan. 23, 2026, profit taking and fresh glioblastoma survival data weighed on a soaring biotech stock.",
    "url": "https://www.fool.com/coverage/stock-market-today/2026/01/23/stock-market-today-jan-23-immunitybio-falls-after-gaining-over-200-in-a-month/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "0ae4b88a-865e-36de-9531-a13b86c897b8",
      "content": {
        "id": "0ae4b88a-865e-36de-9531-a13b86c897b8",
        "contentType": "STORY",
        "title": "Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month",
        "description": "",
        "summary": "Today, Jan. 23, 2026, profit taking and fresh glioblastoma survival data weighed on a soaring biotech stock.",
        "pubDate": "2026-01-23T23:01:46Z",
        "displayTime": "2026-01-23T23:01:46Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/ece2644f62c999828edb4a744e8a56b7",
          "originalWidth": 1401,
          "originalHeight": 1251,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NgY1Ki3DIZazmtFGOnbBXw--~B/aD0xMjUxO3c9MTQwMTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/motleyfool.com/ece2644f62c999828edb4a744e8a56b7.cf.webp",
              "width": 1401,
              "height": 1251,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0zzA8_T8EPIY32gZoC6R8w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/ece2644f62c999828edb4a744e8a56b7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/coverage/stock-market-today/2026/01/23/stock-market-today-jan-23-immunitybio-falls-after-gaining-over-200-in-a-month/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/stock-market-today-jan-23-230146241.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "IBRX"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BNTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]